AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc ... the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Construction spending (Dec.) ISM manufacturing (Jan.) Auto Sales (Jan.) Featured Earnings Palantir Technologies Inc.

Please note that Merck markets Lynparza in partnership with AstraZeneca AZN. AstraZeneca and Merck formed a profit-sharing deal to co-market Lynparza and Koselugo in 2017. AstraZeneca and Merck ...

The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.

AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. AstraZeneca ( NASDAQ:AZN – Get Free Report ) last released its quarterly earnings data on Tuesday, November 12th.

Hector expects AstraZeneca (NASDAQ:AZN) to guide towards a high-single-digit revenue growth for 2025, which would factor in the anticipated effects of Farxiga generics in China. The specifics of ...

The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN) , the Anglo-Swedish Pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months ...